Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920686 · ClinicalTrials.gov registry record · Phase 2
Study of NXN 188 for the Treatment of Migraine With Aura
A Phase 2 study, sponsored by NeurAxon.
- Completed
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
NCT00920686: Completed Phase 2 study, sponsored by NeurAxon.
NCT00920686 is a Phase 2 study that has completed, run by NeurAxon. The registered enrollment target is 239 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920686, a Phase 2 study, has completed, sponsored by NeurAxon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
Study Summary
NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.
Interventions
- DRUG placebo
- DRUG NXN-188
- DRUG sumatriptan succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00920686 record still lists
NCT00920686 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00920686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00920686 about?
NCT00920686 is a clinical study titled "Study of NXN 188 for the Treatment of Migraine With Aura". NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.
What is the current status of trial NCT00920686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2009-06. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00920686?
The interventions under investigation include: placebo (DRUG), NXN-188 (DRUG), sumatriptan succinate (DRUG).
Who is sponsoring clinical trial NCT00920686?
This trial is sponsored by NeurAxon, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00920686's enrollment target sits among peer trials
239 255th of 2000 higher than 1,746 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia